Lialda belongs to a group of medications called aminosalicylates. It is thought that the drug works by inhibiting the production of inflammatory chemicals in the lining of the
colon. Lialda decreases the production of prostaglandins and leukotrienes, chemicals that lead to the inflammation caused by
ulcerative colitis.
Lialda tablets have a special delayed-release coating. This coating prevents the tablets from dissolving until they reach the colon.
Lialda has not been approved for the treatment of ulcerative colitis in children. Be sure to talk with your healthcare provider about the risks and benefits of using the drug in children.
On occasion, your healthcare provider may recommend Lialda for treating something other than ulcerative colitis. This is called an "
off-label" use. At this time, using Lialda to treat
Crohn's disease is considered an off-label use of the drug.